H1F6-MC-MMAF

H1F6-MC-MMAF is an **antibody-drug conjugate (ADC)** composed of a humanized anti-CD70 monoclonal antibody (clone h1F6) conjugated to the cytotoxic drug monomethyl auristatin F (MMAF) via a non-cleavable maleimidocaproyl (MC) linker or, in some versions, a glucuronide-based cleavable linker. The antibody targets CD70, a surface antigen expressed on activated T- and B-lymphocytes as well as various carcinomas, promoting selective delivery of MMAF to tumor cells. Once internalized, MMAF binds tubulin, disrupting microtubule polymerization and inducing cell cycle arrest and apoptosis in cancer cells[1][5]. The ADC has shown preclinical efficacy in inhibiting tumor growth in CD70-expressing cancers and is intended for research use; it has not entered late-stage clinical trials or attained regulatory approval at this time[1][5]. The drug is primarily of interest as a targeted cytotoxic therapy for CD70-positive malignancies.

Other names

h1F6-mcMMAFh-1F6-mcMMAFh 1F6-mcMMAFAnti-CD70 (clone h1F6)-MC-MMAFAnti-CD70-mcMMAFAnti-CD-70-mcMMAFAnti-CD 70-mcMMAF